TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6206124

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 60
Study: 31248769

Group type: EXPERIMENTAL
Intervention: Executive attention training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 70
Study: 29211305

Group type: EXPERIMENTAL
Intervention: BHP+BHCC (patient bone health pamphlet and support from a bone health care coordinator)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: BHP+FP (patient bone health pamphlet and brief recommendations for their family physician)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: BHP+FP
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study: 27163943

Group type: COMPARATOR
Intervention: Cisplatin and etoposide alone (arm A)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide with vismodegib (150 mg/d by mouth; arm B)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide with cixutumumab (6 mg/kg/wk intravenously on day 1; arm C)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Low CTC counts (≤100/7.5 mL) at baseline
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: High CTC counts (>100/7.5 mL) at baseline
Number of subjects: 152
Study: 25281438

Group type: EXPERIMENTAL
Intervention: Bupivacaine-soaked absorbable gelatin sponge
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (no bupivacaine sponge)
Number of subjects: 164
Study: 22679720

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group (CMM or acupuncture combined during rehabilitation)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Conventional treatment group (traditional basic drug treatment)
Number of subjects: 236
Study: 20874488

Group type: EXPERIMENTAL
Intervention: RCTs presented in abstract form at WCE
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: RCTs identified as RCT in the abstract title
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Blinding reported in RCTs
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Compliance with CONSORT checklist
Number of subjects: 94
Study: 18157288

Group type: EXPERIMENTAL
Intervention: Cellfood therapy for six months (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for three months followed by Cellfood for three months (group B)
Number of subjects: 40
Study: 16266223

Group type: EXPERIMENTAL
Intervention: Without drains (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: With two drains (Group II)
Number of subjects: 60
Study: 11978721

Group type: EXPERIMENTAL
Intervention: Problem-based learning health education programme
Number of subjects: 18
Study: 10208507

Group type: EXPERIMENTAL
Intervention: Nickel sulfate (oral administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (intramuscular administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (oral and intramuscular administration)
Number of subjects: 0
Study: 7603419

Group type: EXPERIMENTAL
Intervention: Milk temperature at 37 degrees C (BT group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Milk temperature at 24 degrees C (RT group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Milk temperature at 10 degrees C (CT group)
Number of subjects: 30
Study: 2192695

Group type: EXPERIMENTAL
Intervention: Closed suction (CS) drainage
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sump (S) drainage
Number of subjects: 65
Study: 483364

Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg of body weight (90% coverage)
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg of body weight (60% coverage)
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg of body weight (40% coverage)
Number of subjects: 3056

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg of body weight
Number of subjects: 3056
Study: 31626012

Group type: EXPERIMENTAL
Intervention: Proximal humeral ossification system
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Proximal humeral ossification system combined with Sanders hand system
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Integration of proximal humeral ossification, patient factors, and other classification systems
Number of subjects: 216
Study: 28666680

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine by microneedle patch administered by health-care worker
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine by intramuscular injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo by microneedle patch
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine by self-administered microneedle patch
Number of subjects: 100
Study: 25528738

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 23587521

Group type: EXPERIMENTAL
Intervention: Energy shot without carbohydrates
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 21679319

Group type: EXPERIMENTAL
Intervention: Guided skiing (28.5 days over 12 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no skiing)
Number of subjects: 47
Study: 17869497

Group type: EXPERIMENTAL
Intervention: Aminophylline 5mg/kg/dose diluted in normal saline (NS) solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 60
Study: 16849999

Group type: COMPARATOR
Intervention: Ventilated patients with PCP (V-PCP)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Spontaneously breathing patients with PCP (SB-PCP)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Patients with ARDS
Number of subjects: 95

Group type: COMPARATOR
Intervention: Patients with bacterial pneumonia (PNEU)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Healthy volunteers (control group)
Number of subjects: 95
Study: 12616059

Group type: EXPERIMENTAL
Intervention: Customized exercise program (Group E)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 57
Study: 11819768

Group type: EXPERIMENTAL
Intervention: Omeprazole 2 X 20mg, clarithromycin 2 X 500mg, and amoxicillin 2 X 1g for 7 days
Number of subjects: 167

Group type: COMPARATOR
Intervention: Omeprazole 2 X 20mg plus placebo
Number of subjects: 167
Study: 9424903

Group type: EXPERIMENTAL
Intervention: Collagen in ulcer and surrounding tissue
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Collagen polymorphism study in ulceration
Number of subjects: 15
Study: 7608846

Group type: EXPERIMENTAL
Intervention: Sonic toothbrush
Number of subjects: 51

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 51
Study: 3366345

Group type: EXPERIMENTAL
Intervention: 50 micrograms sulprostone gel
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 100 micrograms sulprostone gel
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pluronic F 127 (control)
Number of subjects: 70
Study: 1916580

Group type: EXPERIMENTAL
Intervention: heparin-containing ointment (50,000 IU heparin/100 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: heparin-free ointment base
Number of subjects: 18
Study: 1071692

Group type: EXPERIMENTAL
Intervention: Prazosin (3 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrallazine (75 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin (1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrallazine (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study: 30601828

Group type: EXPERIMENTAL
Intervention: Cognitive sexual inhibition
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Motivational sexual inhibition
Number of subjects: 22

Group type: COMPARATOR
Intervention: General inhibition task
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both types of sexual inhibition
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inferior frontal gyrus activity
Number of subjects: 22
Study: 28732758

Group type: EXPERIMENTAL
Intervention: Computer-delivered brief intervention with an empathic narrator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computer-delivered brief intervention without an empathic narrator
Number of subjects: 0
Study: 25388481

Group type: EXPERIMENTAL
Intervention: Automated text message appointment reminders (sent at 7, 3, and 1 day before scheduled visits)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 374
Study: 24125402

Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: simvastatin/ezetimibe 10/10 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 153
Study: 21475138

Group type: EXPERIMENTAL
Intervention: Video-based decision aid
Number of subjects: 152

Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 152
Study: 20037560

Group type: EXPERIMENTAL
Intervention: Sinuforte, 10.0 g of amoxilav twice daily, and xylometazole (BID)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amoxilav and xylometazole at the same doses (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sinuforte
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no Sinuforte)
Number of subjects: 50
Study: 17578280

Group type: EXPERIMENTAL
Intervention: autografts of ilium (group A, n=42)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: interbody fusion cages (group B, n=36)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: BMP/artificial bone material/cage (group C, n=36)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study: 12913187

Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg/day
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg/day
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Istradefylline
Number of subjects: 83
Study: 11006499

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol 50 microg/24 h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9117961

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention (recommendations carried out)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No occupational therapy intervention (recommendations not carried out)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No intervention (third group)
Number of subjects: 167
Study: 1500019

Group type: EXPERIMENTAL
Intervention: Three cycles of combination chemotherapy with cisplatin, vinblastine, and bleomycin followed by pelvic radiotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard pelvic radiotherapy
Number of subjects: 71
Study: 6388802

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (1250 mg/M2) and 5-fluorouracil (600 mg/M2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Vincristine (1.5 mg/M2), doxorubicin (50 mg/M2), and cyclophosphamide (500 mg/M2)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CF)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Vincristine, doxorubicin, and cyclophosphamide (VAC)
Number of subjects: 49
Study: 30363041

Group type: EXPERIMENTAL
Intervention: RT performed 3 times per week (RT3)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: RT performed 6 times per week (RT6)
Number of subjects: 27
Study: 27939108

Group type: EXPERIMENTAL
Intervention: Microstream side stream capnography device (quantitative)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Disposable PediCap EtCO2 detector (qualitative)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups (quantitative and qualitative)
Number of subjects: 59
Study: 24947459

Group type: EXPERIMENTAL
Intervention: Balanced 6% HES130/0.42
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ringer-acetate solution
Number of subjects: 50
Study: 23803275

Group type: EXPERIMENTAL
Intervention: mHealth DSS with integrated CIS resources
Number of subjects: 156
Study: 21859411

Group type: EXPERIMENTAL
Intervention: Poetry writing intervention
Number of subjects: 0
Study: 18940024

Group type: EXPERIMENTAL
Intervention: Stress condition (building-site noise at 75 dB with difficult knowledge questions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-stress condition
Number of subjects: 64
Study: 17176348

Group type: EXPERIMENTAL
Intervention: Injection practices assessment
Number of subjects: 1150
Study: 14760332

Group type: EXPERIMENTAL
Intervention: 2.5 mg of carvedilol twice daily
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 10 mg of carvedilol twice daily
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 11156100

Group type: EXPERIMENTAL
Intervention: Tissue valves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical valves
Number of subjects: 0
Study: 9494595

Group type: EXPERIMENTAL
Intervention: Clodronate 300 mg i.v. for 3 days, followed by oral clodronate 3200 mg for four weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 55
Study: 8472160

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 2411103

Group type: EXPERIMENTAL
Intervention: Topical nasal decongestants
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 31137724

Group type: EXPERIMENTAL
Intervention: Deep ocean mineral water (DOM)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study: 30867278

Group type: EXPERIMENTAL
Intervention: Choice of analgesic protocol (low: 50 μg intrathecal morphine, medium: 150 μg intrathecal morphine, high: 300 μg intrathecal morphine with 600 mg oral gabapentin)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: High dose group (300 μg intrathecal morphine with 600 mg oral gabapentin)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Low dose group (50 μg intrathecal morphine)
Number of subjects: 160
Study: 28233752

Group type: EXPERIMENTAL
Intervention: Z-tract technique
Number of subjects: 61

Group type: COMPARATOR
Intervention: Coaxial technique
Number of subjects: 61
Study: 25524791

Group type: EXPERIMENTAL
Intervention: Systematic stimulant treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of stimulants and behavioral treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine community care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent- and teacher-reported ADHD symptoms
Number of subjects: 0
Study: 23953963

Group type: EXPERIMENTAL
Intervention: 61% high porosity asymmetric titanium porous surface (StikTite, Smith and Nephew, TN, USA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 45% low porosity sintered bead porous surface (Roughcoat, Smith and Nephew, TN, USA)
Number of subjects: 62
Study: 21519338

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment at standard doses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CYP3A43 genotype analysis
Number of subjects: 100
Study: 18827109

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment
Number of subjects: 11
Study: 17176376

Group type: EXPERIMENTAL
Intervention: Structured activities intervention group (300 children)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Comparison group (50 children from Gaza and 50 children from the West Bank)
Number of subjects: 400
Study: 14513417

Group type: EXPERIMENTAL
Intervention: 5-drug salvage regimen after 12 weeks of structured treatment interruption (STI)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 5-drug salvage regimen immediately (noninterruption [NI] group])
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 5-drug salvage regimen
Number of subjects: 46
Study: 10846380

Group type: EXPERIMENTAL
Intervention: Midazolam lollipop (5 mg)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Atropine lollipop (0.25 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Midazolam and atropine lollipop (5 mg midazolam and 0.25 mg atropine)
Number of subjects: 175
Study: 9233738

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 61

Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 61
Study: 8481222

Group type: EXPERIMENTAL
Intervention: Kava-special extract WS 1490 (3 x 100 mg/d over 8 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 3436155

Group type: EXPERIMENTAL
Intervention: Indomod (75 mg sustained-release indomethacin)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Indocid R (25 mg normal, 50 mg sustained-release indomethacin)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Indomod
Number of subjects: 18
Study: 29962920

Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaf powder (MLP) fortified foods (MCL-35g and MS-5g)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control food (CF-35g, a cereal legume blend)
Number of subjects: 103
Study: 28232097

Group type: EXPERIMENTAL
Intervention: TF ACD group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MIX ACD group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF ACD group
Number of subjects: 0

Group type: COMPARATOR
Intervention: HC group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TF and MIX groups
Number of subjects: 0
Study: 25605515

Group type: COMPARATOR
Intervention: Macroscopic serosal changes identified intraoperatively in 432 patients (66%)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Macroscopic serosal changes
Number of subjects: 655
Study: 23966331

Group type: EXPERIMENTAL
Intervention: Retinol-binding protein 4
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Vitamin D-binding protein
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Apolipoprotein C-III
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Ceruloplasmin
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Selenoprotein P isoform 1
Number of subjects: 500
Study: 20195164

Group type: EXPERIMENTAL
Intervention: CGES at tachygastrial frequency (12 cycles/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CGES at physiologic frequency (3 cycles/min)
Number of subjects: 20
Study: 18157013

Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer (CIK) cells therapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 85
Study: 16979496

Group type: EXPERIMENTAL
Intervention: Single low-level laser therapy (LLLT); Mini Laser 2075, Helbo Photodynamic Systems GmbH & Co KG, Linz, Austria; wavelength 670 nm, power output 75 mW; duration 30 seconds per banded tooth
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo laser therapy without active laser irradiation
Number of subjects: 76
Study: 14575385

Group type: COMPARATOR
Intervention: 99mTc‐GSA dynamic SPECT study pre-operative
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 99mTc‐GSA dynamic SPECT study post-operative
Number of subjects: 54
Study: 10930199

Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch (HES) 10% 500 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR) 1 L
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8674483

Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.4 ppm for 2 hr)
Number of subjects: 10
Study: 2245382

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (3150 cGy in 18 fractions, 2 to 3 weeks before surgery)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control group (no preoperative radiation)
Number of subjects: 309
Study: 654857

Group type: EXPERIMENTAL
Intervention: Furosemide, 1 mg/kg b.w.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mannitol, 0.5 g/kg b.w.
Number of subjects: 16
Study: 31531854

Group type: EXPERIMENTAL
Intervention: Fentanyl intravenous patient-controlled analgesia
Number of subjects: 22144

Group type: EXPERIMENTAL
Intervention: Dynamic predictive model
Number of subjects: 22144
Study: 30003833

Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo effect model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 0
Study: 28662208

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 91
Study: 25027945

Group type: EXPERIMENTAL
Intervention: Desflurane (1MAC, 5-6%)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.5-2%)
Number of subjects: 31
Study: 23253266

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26
Study: 22068809

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: simvastatin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: combination of both
Number of subjects: 66
Study: 18076072

Group type: EXPERIMENTAL
Intervention: Congenital malformations
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Maternal history of spontaneous abortions
Number of subjects: 191
Study: 17044456

Group type: EXPERIMENTAL
Intervention: Sureflux 150E (cellulose triacetate)
Number of subjects: 17

Group type: COMPARATOR
Intervention: AV-400 (standard synthetic membrane)
Number of subjects: 17
Study: 15189628

Group type: EXPERIMENTAL
Intervention: Self-enhancement values salient
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-transcendence values salient
Number of subjects: 0